PCR/qPCR solution will support surveillance and monitoring of the current H5N1 strain of bird flu in response to multi-state outbreak in U.S. dairy cows

Amidst growing concerns from U.S. federal, state and local agencies over Highly Pathogenic Avian Influenza (HPAI) A (H5N1) detections in dairy cows, Integrated DNA Technologies today launched the Avian Influenza Type A (H5) Primers and Probe Set to enable researchers to identify, target, and trace the presence of clade 2.3.4.4b of the H5N1 virus across bird, environmental, dairy cow, and poultry farm samples. The new offering is available for online ordering through IDT’s Tech Access Program, which enables access to the most advanced research tools in development to accelerate innovation. IDT’s Avian Influenza A (H5) Primers and Probe Set is manufactured in a certified, template-free environment and includes an internal control to help confirm false negatives. An Avian Influenza Positive Sample Control is also available for purchase.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610629392/en/

Integrated DNA Technologies today launched the Avian Influenza Type A (H5) Primers and Probe Set to enable researchers to identify, target, and trace the presence of clade 2.3.4.4b of the H5N1 virus across bird, environmental, dairy cow, and poultry farm samples. (Photo: Business Wire)

“IDT is proud to leverage its track record in viral surveillance and response to be a trusted partner for researchers looking to understand, monitor, and control the spread of Avian flu,” said Demaris Mills, President, Integrated DNA Technologies. “As one of the first to market a differentiated offering for the current clade of the H5N1 virus, we have designed a much-needed solution to aid avian influenza research, surveillance, vaccine development, and public health preparedness efforts, ultimately contributing to U.S. and worldwide initiatives focused on early detection and mitigation of future outbreaks.”

The Avian Influenza A (H5) Primers and Probe Set is compatible with IDT’s PrimeTime™ 1-Step 4X Broad-Range qPCR Master Mix. Formulated as an inhibitor resistant, high-performance master mix that allows for direct amplification of crude samples, the one-step Master Mix provides researchers with a premium option that can save time and costs associated with doing extractions from viral transport media (VTM) prior to the amplification step, helping to enrich endpoint florescence and optimize data confidence. The Master Mix features an exclusive mutant enzyme ideal for viral research.

IDT has a rich history of supporting infectious disease and viral surveillance efforts, innovating on its product portfolio with unique solutions that enable researchers and public health officials to rapidly respond, control, and develop effective measures. Last year, it launched a next generation sequencing (NGS) solution made for respiratory viruses, and a complete NGS library preparation solution for mpox the previous year. The company also played an important role in the fight against COVID-19 as the first company in the nation to be trusted by the Centers for Disease Control and Prevention to supply critical reagents used during the pandemic.

To order the Avian Influenza Type A (H5) Primers and Probe Set, visit www.idtdna.com/AvianFlu.

For additional product information and to download the Avian Influenza Type A (H5) Primers and Probe Set protocol, click here.

About IDT

For more than 35 years, Integrated DNA Technologies, Inc. (IDT) has empowered genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, featuring the most advanced synthesis, modification, purification, and quality control capabilities available. Since its founding in 1987, IDT has progressed from a leading oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases.

Seeking to fulfill its mission of accelerating the pace of genomics, IDT acquired Archer™ NGS Research Assays in December 2022. When combined with its existing solutions, the expanded portfolio helps realize the shared vision of enabling researchers to rapidly move from the lab to life-changing advances.

IDT’s infrastructure supports customers around the globe with its manufacturing headquarters situated in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Boulder, Colorado, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.

IDT is proud to be part of Danaher. Danaher’s science and technology leadership puts IDT’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.

Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Doc ID: RUO24-2946_001

View source version on businesswire.com: https://www.businesswire.com/news/home/20240610629392/en/